One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
      • Luxury & premium products
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Healthcare IT
      • Medical Devices & Supplies
      • Pharmaceuticals
    • Food and Beverage
      • Agriculture & Agri Products
      • Beverages
      • Food Ingredients
      • Food Services and Hospitality
      • Nutraceutical | Wellness Food
      • Processed & Frozen Foods
    • Automotive and Transportation
      • Automotive components
      • Automotive Logistics
      • Automotive systems and accessories
    • Information and Communications Technology
      • E Commerce and Outsourcing
      • Entertainment & Media
      • High Tech | Enterprise & Consumer IT
      • Information & Network Security
      • Mobility | Telecom & Wireless
      • Software and Services
    • Semiconductor and Electronics
      • Semiconductor Materials and Components
      • Display Technology
      • Electronics System and Components
      • Emerging technologies
      • Security and Surveillance
      • Sensors and Controls
    • Building and Construction
      • Construction Materials
      • HVAC
      • Residential Construction and Improvement
      • Roads & Highways
    • Manufacturing
      • Manufacturing Services
      • Heavy Manufacturing
      • Packaging
      • Engineering | Equipment and Machinery
  • Who Trust Us
  • [email protected]
  • +1 718 874 1545 (International)
  • +91 78878 22626 (Asia)

More Results

One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
      • Luxury & premium products
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Healthcare IT
      • Medical Devices & Supplies
      • Pharmaceuticals
    • Food and Beverage
      • Agriculture & Agri Products
      • Beverages
      • Food Ingredients
      • Food Services and Hospitality
      • Nutraceutical | Wellness Food
      • Processed & Frozen Foods
    • Automotive and Transportation
      • Automotive components
      • Automotive Logistics
      • Automotive systems and accessories
    • Information and Communications Technology
      • E Commerce and Outsourcing
      • Entertainment & Media
      • High Tech | Enterprise & Consumer IT
      • Information & Network Security
      • Mobility | Telecom & Wireless
      • Software and Services
    • Semiconductor and Electronics
      • Semiconductor Materials and Components
      • Display Technology
      • Electronics System and Components
      • Emerging technologies
      • Security and Surveillance
      • Sensors and Controls
    • Building and Construction
      • Construction Materials
      • HVAC
      • Residential Construction and Improvement
      • Roads & Highways
    • Manufacturing
      • Manufacturing Services
      • Heavy Manufacturing
      • Packaging
      • Engineering | Equipment and Machinery
  • Who Trust Us
Home ➤ Life Science ➤ Pharmaceuticals ➤ Cancer Immunotherapy Market
Cancer Immunotherapy Market
Cancer Immunotherapy Market
Published date: Nov 2023 • Formats:
Request Sample Schedule a Call
  • Home ➤ Life Science ➤ Pharmaceuticals ➤ Cancer Immunotherapy Market

Global Cancer Immunotherapy Market By Technology Type (Monoclonal Antibodies, Cytokines & Immunomodulators, and Others), By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others), By End-user (Hospitals, Cancer Research Centers, and Clinics), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032

  • Published date: Nov 2023
  • Report ID: 67380
  • Number of Pages: 294
  • Format:
  • Overview
  • Table of Contents
  • Major Market Players
  • Request a Free Sample
  • Quick Navigation

    • Report Overview
    • Key Takeaways
    • Application Analysis
    • End-User Analysis
    • Key Market Segments
    • Drivers
    • Restraints
    • Opportunity
    • Trends
    • Key Players Analysis
    • Report Scope

    Report Overview

    Global Cancer Immunotherapy Market size is expected to be worth around USD 674 Billion by 2032 from USD 191 Billion in 2022, growing at a CAGR of 13.8% during the forecast period from 2022 to 2032.

    A cancer treatment called cancer immunotherapy enhances the immune system’s ability against cancer. This treatment is better than the older technique, as it offers long-term protection against cancer, has fewer side effects, and can treat a wider variety of cancers. Different types of cancers can be treated with immunotherapy, including breast cancer, prostate cancer, and colorectal cancer.

    Immunotherapy directs the immune system towards cancer-specific targets and activates the immune system to mobilize that target. This triggers a response capable of destroying cancer cells. The industry will continue to grow due to the rising incidence of cancer. The market is expected to gain momentum during the forecast period due to increased awareness about the importance of cancer immunotherapy.

    The growth of the market for cancer immunotherapy is expected to be slowed by strict regulations. The government has better oversight over immunotherapy use and is responsible for clinical trials. This makes it more difficult for companies to enter the market and will likely hinder their growth. The market for cancer immunotherapy is expected to be hampered by the high cost of product development.

    Cancer Immunotherapy Market Value

    *Actual Numbers Might Vary In The Final Report

    Key Takeaways

    • The Cancer Immunotherapy Market is expected to reach USD 674 billion by 2032.
    • The market is growing at a rate of 13.8% annually.
    • Increasing prevalence of cancer and R&D efforts drive market growth.
    • In 2022, the market was valued at USD 191 billion.
    • Monoclonal antibodies and lung cancer treatments had a significant market share in 2022.
    • Lung cancer treatment dominated the market share in 2023-2032.
    • Hospitals are a major end-user of cancer immunotherapy.
    • North America held the highest revenue share 43% in 2022.
    • Europe had a revenue share of 25% in 2022.
    • Factors driving market growth include the rising global cancer prevalence and technological advancements.
    • Pharmaceutical companies invest heavily in R&D for cancer immunotherapies.
    • Governments globally support cancer immunotherapy research.
    • High treatment costs are a challenge for the market’s growth.

    Technology Type Analysis

    Monoclonal antibodies and the Lung Cancer segment account significant share of the global cancer immunotherapy market in 2022

    The cancer immunotherapy market can be divided by technology type into monoclonal antibodies, cytokines, immunomodulators, and others. The largest share of monoclonal antibody sales in 2022 was due to the increased use of monoclonal antibodies for cancer immunotherapy. They have different properties that allow the immune system to be modulated and can therefore activate or inhibit specific molecules. Monoclonal antibodies can also trigger the antitumor immune reaction.

    Application Analysis

    lung cancer segment held the largest market share

    The cancer immunotherapy market can be divided by application into five segments: lung cancer; breast cancer; colorectal cancer; prostate cancer; head and neck cancer, as well as other applications. Due to the high incidence of lung disease worldwide and the increase in awareness about the importance of early treatment, the market for lung cancer held the largest market share in 2022. It is expected to be the cancer immunotherapy market leader during the analysis period.

    End-User Analysis

    The hospital segment will account for a significant share of the global cancer immunotherapy market in 2022

    Due to rising disease prevalence, increased awareness, increased treatment rates, and increased diagnosis of malignancies and the large number of hospitals offering immunotherapy treatments, the hospital segment will be the largest in recent years. Hospitals are increasingly using immunotherapy treatments to treat cancer conditions. According to Elsevier Inc.’s report, the number of patients receiving treatment at hospitals for melanoma is on the rise. It rose from 14.5% to 37% in 90 days after diagnosis.

    The forecast period will see the cancer research centers segment grow rapidly. This segment growth can be attributed to increased oncology research and ongoing support activities by non-governmental organizations in the form of grants and funding to spur forward demand.

    Cancer Immunotherapy Market

    Key Market Segments

    By Technology Type

    • Monoclonal Antibodies
    • Cytokines & Immunomodulators
    • Others

    By Application

    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Melanoma
    • Prostate Cancer
    • Head & Neck Cancer
    • Others

    By End-user

    • Hospitals
    • Cancer Research Centers
    • Clinics

    Drivers

    Increasing prevalence of oncology

    The cancer immunotherapy market is driven by the increasing prevalence of oncology around the world and a rise in R&D efforts to develop novel oncology therapies. Market growth will also be driven by the existence of many organizations that support immunotherapy research. The Parker Institute for Cancer Immunotherapy, for example, collaborated with industry leaders and researchers to create breakthrough immunotherapies for cancer.

    The Global Cancer Observatory estimates that the United States reported approximately 2,281,658 cases of cancer in 2020 and 612,390 deaths related to cancer. The most common types of malignancies in the U.S. are breast, prostate, and lung cancers. According to the Cancer Council, Australia had 150,000 new cases of cancer and 50,000 deaths in 2020. Cancer immunotherapy market expansion is expected to be accelerated by the rising number of malignant tumors.

    Increasing approval of new immunotherapies

    Market growth is expected to be driven by the increasing approval of new immunotherapies. The U.S. FDA approved several anti-PD-1 antibodies during 2020-2022. These include nivolumab and avelumab and dostarlimab. They are used to treat NSCLC, renal cancer, melanoma, and breast malignancies. Market growth has been accelerated by the higher approvals for immunotherapeutic agents.

    Restraints

    High Cost of Cancer Immunotherapy Manufacturing Research and Development to Hamper Global Market Growth.

    The global cancer immunotherapy market concerns both manufacturing and research costs, as well as the market price for end-users. Cancer immunotherapy research and development is expensive for developing organizations, so it can be difficult to obtain funds. Innovations that involve research require substantial investment.

    The innovator is likely to receive significant profits. High investment is required for cancer immunotherapy. Companies are hesitant to enter this market because they don’t know if they will make a profit.

    Opportunity

    Increase R&D efforts to develop cancer immunotherapy

    Cancer immunotherapy market expansion is enhanced by the presence of non-governmental and government organizations that promote awareness and research. Cancer Research Institute, for example, funded over 120 clinical trials and spent approximately USD 474 million on research. The Society for Immunotherapy of Cancer (SITC), on the other hand, is committed to improving patient outcomes through the advancement of science and the application of immunotherapy for cancer.

    These organizations work with scientists and researchers to develop new treatment options for immune therapy. In addition, funding increases for the development and testing of new treatments are expected to increase R&D efforts to develop cancer immunotherapy.

    In June 2022, a Stanford team received US$ 13 million in funding from Cancer Grand Challenges. This funding initiative was initiated by Cancer Research UK and the U.S. National Cancer Institute. This funding will be used to develop next-generation immunotherapies and study extrachromosomal genetic material. It also helps with early-stage malignancies.

    Trends

    Advanced technologies in cancer immunotherapy are becoming a popular trend in the market

    The cancer immunotherapy market has seen a rise in the number of therapies and technologies that can be used to aid the immune system to identify and attack cancerous cells. These include immuno-oncology and cryoablation as well as bone marrow transplant and radiation therapy. These technologies can make a huge difference in the treatment and cure of cancer.

    AstraZeneca plc (a UK-based pharmaceutical company and biotechnology company) announced in October 2022 that Capivasertib, which is combined with Faslodex, had been approved. This is a breast cancer immunotherapeutic that was developed to treat breast cancer. It is effective in recurrence and advancement of endocrine therapy in locally advanced or metastatic breast cancers with low or negative human Epidermal Growth Factor 2 (HER2), as well as in the management of HER2+.
    Regional Analysis

    North America region accounted significant share of the global cancer immunotherapy market in 2022

    Regional analysis shows that North America was the largest revenue contributor. This can be attributed to the sharp rise in healthcare expenditures, increased emphasis on maintaining the best healthcare system, and an increase in cancer incidence worldwide. North America is expected to be a lucrative market for cancer immunotherapy in the future.

    The region’s market is driven by well-developed healthcare infrastructure and increased government initiatives. North America’s high market share can be attributed primarily to the rise in cancer patients, increased adoption of immunotherapy, and the development of bioinformatics tools that improve drug development. The highest projected CAGR for Asia-Pacific during the analysis period is due to the rise in healthcare spending, the surge in per-capita income, and improvements in healthcare infrastructure.

    Europe will be the second most revenue-shared region during the forecast period due to its infrastructure development and rising incidences. Asia Pacific will experience the fastest growth over the forecast period. In China and Japan, new and more advanced immunotherapy drugs were introduced. There are ongoing clinical trials in these countries, as well as FDA approvals for combination therapies and new drug molecules. The approval of new treatment drugs in China or Japan increases the acceptance of immunotherapy to treat tumors.

    Cancer Immunotherapy Market Region

    Key Regions

    • North America
      • The US
      • Canada
      • Mexico
    • Western Europe
      • Germany
      • France
      • The UK
      • Spain
      • Italy
      • Portugal
      • Ireland
      • Austria
      • Switzerland
      • Benelux
      • Nordic
      • Rest of Western Europe
    • Eastern Europe
      • Russia
      • Poland
      • The Czech Republic
      • Greece
      • Rest of Eastern Europe
    • APAC
      • China
      • Japan
      • South Korea
      • India
      • Australia & New Zealand
      • Indonesia
      • Malaysia
      • Philippines
      • Singapore
      • Thailand
      • Vietnam
      • Rest of APAC
    • Latin America
      • Brazil
      • Colombia
      • Chile
      • Argentina
      • Costa Rica
      • Rest of Latin America
    • Middle East & Africa
      • Algeria
      • Egypt
      • Israel
      • Kuwait
      • Nigeria
      • Saudi Arabia
      • South Africa
      • Turkey
      • United Arab Emirates
      • Rest of MEA

    Key Players Analysis

    There is a fragmented market for cancer immunotherapy. Both at the global and regional levels, there are many major players. Key players participate in product development and strategic alliances to expand their product portfolios and strengthen their position in the global market. Market demand will be supported by several strategic initiatives taken by top players.

    Market Key Players

    Market players are subject to intense competition from top market players, particularly those with strong brand recognition and high distribution networks. To stay on top of the market, companies have gained various expansion strategies such as partnerships and product launches.

    The following are some of the major players in the global cancer immunotherapy industry

    • Amgen Inc.
    • Bayer AG
    • AstraZeneca PLC
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd. (Genentech Inc.)
    • Pfizer Inc.
    • Eli Lily and Company
    • Novartis AG
    • Johnson & Johnson (Janssen Global Services LLC)
    • Merck KGAA
    • Other Key Players.

    Recent Development

    • 2022 Feb: Janssen Pharmaceutical Companies of Johnson & Johnson reported that CARVYKTI was approved by the U.S. Food and Drug Administration for the treatment of adults with relapsed/refractory multiple myeloma.
    • 2022 Feb: Medigene AG and BioNTech Se collaborated to develop immunotherapies based on T-cell receptors for cancer.
    • 2021 April: The U.S. Food and Drug Administration approved Opdivo (nivolumab) in collaboration with other chemotherapy for the first treatment of patients with advanced, metastatic, or gastroesophageal cancers, as well as esophageal cancer. This is the FDA’s first approved immunotherapy to treat gastric cancer.
    • August 2022: Genmab A/S and BioNTech SE expanded their strategic partnership for the development and launched new immunotherapies for various types of cancer.
    • 2022 March: Merck & Co., Inc also announced the approval of KEYTRUDA by the U.S. FDA, an anti-PD-1 treatment for advanced endometrial cancer, is available.

    Report Scope

    Report Features Description
    Market Value (2022) USD  191 Billion
    Forecast Revenue (2032) USD  674 Billion
    CAGR (2023-2032) 13.8 %
    Base Year for Estimation 2022
    Historic Period 2016-2021
    Forecast Period 2023-2032
    Report Coverage Revenue Forecast, Market Dynamics, Competitive Landscape, Recent Developments
    Segments Covered By Technology Type- Monoclonal Antibodies, Cytokines & Immunomodulators, and Others; By Application- Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others; and By End-user- Hospitals, Cancer Research Centers, and Clinics
    Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA
    Competitive Landscape Amgen Inc., Bayer AG, AstraZeneca PLC, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Pfizer Inc., Eli Lily and Company, Novartis AG, Johnson & Johnson (Janssen Global Services, LLC), Merck KGAA, Other Key Players.
    Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements.
    Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)

    Frequently Asked Questions (FAQ)

    How much is the Global Cancer Immunotherapy Market worth?

    Global market size is worth USD 674 Billion by 2032.

    What was the value of the Cancer Immunotherapy Market in 2023?

    In 2023, the market value stood at USD 191 Billion.

    What is the CAGR of Cancer Immunotherapy Market?

    The Global Cancer Immunotherapy Market is growing at a CAGR of 13.8% during the forecast period 2022 to 2033.

    Who are the major players operating in the Cancer Immunotherapy Market?

    Amgen Inc., Bayer AG, AstraZeneca PLC, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Pfizer Inc., Eli Lily and Company, Novartis AG, Johnson & Johnson (Janssen Global Services, LLC), Merck KGAA, Other Key Players.

    Which region will lead the global Cancer Immunotherapy Market?

    North America is estimated to be the fastest-growing region during the forthcoming years.

    Cancer Immunotherapy Market
    Cancer Immunotherapy Market
    Published date: Nov 2023
    add_shopping_cartBuy Now get_appDownload Sample
    keyboard_arrow_up
    • Amgen Inc.
    • Bayer AG Company Profile
    • AstraZeneca Plc Company Profile
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd. (Genentech Inc.)
    • Pfizer Inc Company Profile
    • Eli Lily and Company
    • Novartis AG Company Profile
    • Johnson & Johnson (Janssen Global Services LLC)
    • Merck KGaA Company Profile
    • Other Key Players.
  • settingsSettings

Related Reports

  • Autoimmune Disease Diagnostics Market
  • Intravenous Immunoglobulin Market
  • Immune Thrombocytopenia Market
  • Immunoassays Market
  • Cancer Immunotherapy Market
  • RNA Analysis Market

Our Clients

  • Our Clients
Inquiry Before Buying

Cancer Immunotherapy Market
  • 67380
  • Nov 2023
    • ★★★★★
      ★★★★★
    • (58)
add_shopping_cart Buy Now
Trusted by more than 17382 organizations globally
  • Client Logo
  • Client Logo
  • Client Logo
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$6,000
$3,999
USD / per unit
save 24%
Multi User
$8,000
$5,999
USD / per unit
save 28%
Corporate User
$10,000
$6,999
USD / per unit
save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 3,999) Buy Now ($ 5,999) Buy Now ($ 6,999)
  • location_on420 Lexington Avenue, Suite 300 New York City, NY 10170,
    United States
  • phone+1 718 874 1545 (International)
  • phone+91 78878 22626 (Asia)
  • email[email protected]
  • Facebook Logo
  • Twitter Logo
  • LinkedIn Logo
Find Help
  • Contact Us
  • How to Order
Legal
  • Privacy Policy
  • Refund Policy
  • Frequently Asked Questions
  • Terms and Conditions
Explore
  • About Us
  • All Reports
  • All Sectors
  • Infographics
  • Statistics and Facts
  • Companies
Secured Payment Options
Secured Payment Options

© 2025 Market.Us. All Rights Reserved.